Pneumocystis pneumonia associated with infliximab in Japan [16]

New England Journal of Medicine

Volumn 357, Issue 18, 2007, Pages 1874-1876

  Harigai, Masayoshi ^a   Koike, Ryuji ^a   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; JAPAN; LETTER; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 35748983554     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070728     Document Type: Letter

References (5)

1. Miyasaka N, Takeuchi T, Eguchi K. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 2005;15:48. [Erratum, Mod Rheumatol 2005;15:322.]
2. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis (in press).
3. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:31524.
4. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001;344:16874.
5. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) betaDglucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996;3:1979